Amuvatinib

Drug Profile

Amuvatinib

Alternative Names: HPK-56; MP-470

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Montigen
  • Developer Astex Pharmaceuticals
  • Class Amides; Antineoplastics; Small molecules
  • Mechanism of Action DNA repair inhibitors; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c-kit inhibitors; Rad51 recombinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Glioblastoma; Small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 21 Sep 2012 Efficacy data from the phase II ESCAPE trial in Small cell lung cancer released by Astex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top